CA3021677C - USE OF BETA-AGONISTS OF THYROID HORMONES - Google Patents

USE OF BETA-AGONISTS OF THYROID HORMONES

Info

Publication number
CA3021677C
CA3021677C CA3021677A CA3021677A CA3021677C CA 3021677 C CA3021677 C CA 3021677C CA 3021677 A CA3021677 A CA 3021677A CA 3021677 A CA3021677 A CA 3021677A CA 3021677 C CA3021677 C CA 3021677C
Authority
CA
Canada
Prior art keywords
group
alkyl
compound
optionally substituted
hormone receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3021677A
Other languages
English (en)
French (fr)
Other versions
CA3021677A1 (en
Inventor
Brian Lian
Rochelle Hanley
Misha Dinerman
Original Assignee
Viking Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viking Therapeutics Inc filed Critical Viking Therapeutics Inc
Publication of CA3021677A1 publication Critical patent/CA3021677A1/en
Application granted granted Critical
Publication of CA3021677C publication Critical patent/CA3021677C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
CA3021677A 2016-04-22 2017-04-24 USE OF BETA-AGONISTS OF THYROID HORMONES Active CA3021677C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662326431P 2016-04-22 2016-04-22
US62/326,431 2016-04-22
PCT/US2017/029102 WO2017185083A1 (en) 2016-04-22 2017-04-24 Use of thyroid beta-agonists

Publications (2)

Publication Number Publication Date
CA3021677A1 CA3021677A1 (en) 2017-10-26
CA3021677C true CA3021677C (en) 2024-11-12

Family

ID=60117062

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3021677A Active CA3021677C (en) 2016-04-22 2017-04-24 USE OF BETA-AGONISTS OF THYROID HORMONES

Country Status (10)

Country Link
US (1) US20190134069A1 (https=)
EP (1) EP3445372B1 (https=)
JP (1) JP2019515915A (https=)
KR (1) KR102407053B1 (https=)
CN (3) CN110200978B (https=)
AU (2) AU2017252122B2 (https=)
BR (1) BR112018071559B1 (https=)
CA (1) CA3021677C (https=)
MX (1) MX2018012904A (https=)
WO (1) WO2017185083A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3445373B1 (en) 2016-04-22 2024-08-21 Viking Therapeutics, Inc. Use of thyroid beta-agonists
US11752161B2 (en) 2020-03-27 2023-09-12 Gannex Pharma Co., Ltd. Pharmaceutical compositions, method of making and method of using thereof
JP2025520449A (ja) * 2022-06-15 2025-07-03 バイキング セラピューティクス，インコーポレーテッド Ｘ－ａｌｄ治療のための甲状腺ベータ作動薬投与計画

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
US5091552A (en) 1986-06-30 1992-02-25 Board Of Regents, The University Of Texas System Novel antitumor aldophosphamide analogs
ATE131825T1 (de) 1990-06-13 1996-01-15 Arnold Glazier Phosphorylierte prodrugs
US5157027A (en) 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
ATE199906T1 (de) 1993-06-29 2001-04-15 Mitsubishi Chem Corp Phosphonat-nukleotid ester-derivate
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
DK0999825T3 (da) 1997-07-29 2004-02-09 Alcon Lab Inc Oftalmiske sammensætninger indeholdende galactomannanpolymerer og borater
US6110973A (en) 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
CA2534484A1 (en) 2003-08-07 2005-02-17 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using same
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
CA2543132A1 (en) * 2003-10-23 2005-05-19 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
WO2006128058A2 (en) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
CA2638753A1 (en) * 2004-12-08 2006-06-15 Sirion Therapeutics, Inc. Methods, assays and compositions for treating retinol-related diseases
EP1987827A1 (en) * 2006-02-20 2008-11-05 Takeda Pharmaceutical Company Limited Novel pharmaceutical
WO2011038207A1 (en) 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
HUE038366T2 (hu) * 2010-08-16 2018-10-29 Allergan Inc Módszer szabályozó T-sejtek alfa-2B adrenerg receptor agonistákkal való aktiválásához
WO2014178892A1 (en) * 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
EP3259246B1 (en) * 2015-02-20 2023-03-22 Oregon Health & Science University Derivatives of sobetirome
EP3423379B1 (en) * 2016-02-29 2020-04-01 Philip Morris Products S.a.s. Hinge-lid container and blank
CN109475121B (zh) * 2016-05-18 2021-06-25 俄勒冈健康科学大学 苏比替罗衍生物

Also Published As

Publication number Publication date
AU2017252122A1 (en) 2018-11-15
EP3445372A4 (en) 2020-03-25
KR20190017748A (ko) 2019-02-20
AU2023202321A1 (en) 2023-05-11
KR102407053B1 (ko) 2022-06-10
BR112018071559B1 (pt) 2024-02-06
CN113730421A (zh) 2021-12-03
WO2017185083A1 (en) 2017-10-26
CN110200978A (zh) 2019-09-06
US20190134069A1 (en) 2019-05-09
AU2023202321B2 (en) 2025-04-24
AU2017252122B2 (en) 2023-02-09
CA3021677A1 (en) 2017-10-26
CN109641003A (zh) 2019-04-16
EP3445372B1 (en) 2026-02-25
MX2018012904A (es) 2019-01-31
EP3445372A1 (en) 2019-02-27
JP2019515915A (ja) 2019-06-13
CN110200978B (zh) 2023-10-31
BR112018071559A2 (pt) 2019-05-14

Similar Documents

Publication Publication Date Title
US12440502B2 (en) Use of thyroid beta-agonists
AU2023202321B2 (en) Use of thyroid beta-agonists
CN110730664A (zh) 含谷氨酰胺酶抑制剂的组合疗法
US11382908B2 (en) Compositions and methods for treating inflammatory bowel disease
UA123700C2 (uk) Композиції і способи інгібування активності аргінази
HK40064933A (en) Use of thyroid beta-agonists
HK40013781A (en) Use of thyroid beta-agonists
HK40007271A (en) Use of thyroid beta-agonists
HK40013781B (zh) 甲状腺β-激动剂的应用
US20200338098A1 (en) Conjoint Therapies with Inhibitors of Glucose Production
WO2017127417A1 (en) Phosphopantothenate compounds

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220420

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20241108

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20241112

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250401

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250516

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260331

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260331